(Total Views: 547)
Posted On: 12/11/2023 1:29:49 PM
Post# of 148870
Thanks, CGC! Great stuff, and 2 questions:
1. I didn't see any reference to possible Alzheimers efficacy in your summary, likely because it's just a theoretical application at this point. But I have seen something called "Pepinemab" being developed to potentially treat Alzheimer’s, so -
Do you know if Leronlimab would have a similar MOA as Pepinemab? Or is Pepinemab better suited to tackle Alzheimer’s than Leronlimab?
2. Your write up mentioned 800 patients treated with Leronlimab - but isn't it over a 1,000? I thought I read where Dr J stated "over a thousand" in one of his talks.
Thanks again for your summary!
1. I didn't see any reference to possible Alzheimers efficacy in your summary, likely because it's just a theoretical application at this point. But I have seen something called "Pepinemab" being developed to potentially treat Alzheimer’s, so -
Do you know if Leronlimab would have a similar MOA as Pepinemab? Or is Pepinemab better suited to tackle Alzheimer’s than Leronlimab?
2. Your write up mentioned 800 patients treated with Leronlimab - but isn't it over a 1,000? I thought I read where Dr J stated "over a thousand" in one of his talks.
Thanks again for your summary!
(2)
(0)Scroll down for more posts ▼
